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SCIENTIFIC OPINION  
Scientific Opinion on Flavouring Group Evaluation 305 (FGE.305):  
L-Methionylglycine of chemical group 341
EFSA Panel on Food Contact Materials, Enzymes,  
Flavourings and Processing Aids (CEF)
 
2, 3
European Food Safety Authority (EFSA), Parma, Italy 
  
ABSTRACT 
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European Food Safety 
Authority was requested to evaluate one flavouring substance, the dipeptide L-methionylglycine [FL-no: 17.037], 
in the Flavouring Group Evaluation 305, using the Procedure in Commission Regulation (EC) No 1565/2000. 
The substance was considered not to have genotoxic potential. The substance was evaluated through a stepwise 
approach (the Procedure) that integrates information on the structure-activity relationships, intake from current 
uses, toxicological threshold of concern, and available data on metabolism and toxicity. The Panel concluded that 
for the flavouring substance, evaluated through the Procedure, no appropriate NOAEL was available and 
additional data are required. The present evaluation of the candidate substance L-methionylglycine [FL-no: 
17.037] is only applicable for its use in foods that are not heated or intended to be heated. Besides the safety 
assessment of the flavouring substance, the specifications for the material of commerce have also been 
considered. Adequate specifications including complete purity criteria and identity for the material of commerce 
have been provided for the candidate substance. 
© European Food Safety Authority, 2013 
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SUMMARY  
Following a request from the European Commission the Panel on Food Contact Materials, Enzymes, 
Flavourings and Processing Aids (CEF Panel) was asked to deliver a scientific opinion on the 
implications for human health of chemically defined flavouring substances used in or on foodstuffs in 
the Member States. In particular, the Panel was requested to evaluate one flavouring substance, the 
dipeptide L-methionylglycine [FL-no: 17.037], in the Flavouring Group Evaluation 305 (FGE.305), 
using the Procedure as referred to in the Commission Regulation (EC) No 1565/20004
The candidate substance possesses one chiral centre and the optical isomer has been specified.  
. This 
flavouring substance belongs to chemical group 34, Annex I of the Commission Regulation (EC) No 
1565/2000. 
The candidate substance belongs to structural class III and has not been reported to occur naturally in 
any food items according to TNO.  
In its evaluation, the Panel as a default used the Maximised Survey-derived Daily Intake (MSDI) 
approach to estimate the per capita intakes of the flavouring substances in Europe. However, when 
the Panel examined the information provided by the European Flavouring Industry on the use levels in 
various foods, it appeared obvious that the MSDI approach in a number of cases would grossly 
underestimate the intake by regular consumers of products flavoured at the use level reported by the 
Industry, especially in those cases where the annual production values were reported to be small. In 
consequence, the Panel had reservations about the data on use and use levels provided and the intake 
estimates obtained by the MSDI approach.  
In the absence of more precise information that would enable the Panel to make a more realistic 
estimate of the intakes of the flavouring substances, the Panel has decided also to perform an estimate 
of the daily intakes per person using a modified Theoretical Added Maximum Daily Intake 
(mTAMDI) approach based on the normal use levels reported by Industry. In those cases where the 
mTAMDI approach indicated that the intake of a flavouring substance might exceed its corresponding 
threshold of concern, the Panel decided not to carry out a formal safety assessment using the 
Procedure. In these cases the Panel requires more precise data on use and use levels. 
According to the default MSDI approach the intake in Europe for the candidate substance L-
methionylglycine [FL-no: 17.037] is 1.2 µg/capita/day.  
No data on genotoxicity has been submitted for the candidate substance. However, consideration of 
the chemical structure does not give rise to safety concern with respect to genotoxicity. 
No information has been provided on hydrolysis of the candidate substance L-methionylglycine [FL-
no: 17.037] under physiological conditions. Without information about the potential for hydrolysis of 
the candidate substance L-methionylglycine [FL-no: 17.037] and without any studies that show the 
fate of the substance in vitro and/or in vivo, it is not possible to predict whether it will be absorbed as 
a dipeptide or not, nor its distribution or potential bioactivity after absorption. Since such information 
is lacking, rapid metabolism of the dipeptide to innocuous metabolites cannot be anticipated. 
Therefore, evaluation of the candidate substance proceeds via the B-side to step B4 of the Procedure, 
at which step no adequate study from which a No Observed Adverse Effect Level (NOAEL) was 
available. So, the Panel concluded that additional data are required for the candidate substance L-
methionylglycine [FL-no: 17.037]. 
                                                     
4 Commission Regulation No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an 
evaluation programme in application of Regulation (EC) No 2232/96. Official Journal of the European Communities 
19.7.2000, L 180, 8-16. 
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When the estimated intake was based on the mTAMDI, it was 24000 µg/person/day, which is above 
the threshold for structural class III of 90 µg/person/day.  
The Panel noted the high discrepancy between MSDI and mTAMDI. The hypothetical nature of the 
MSDI, which is based on anticipated volumes of production, leads to a high uncertainty in the safety 
evaluation of this substance when based on the MSDI. The Panel will therefore not be in a position to 
conclude on the absence of safety concern for this specific substance unless a more refined dietary 
exposure estimate based on use levels is provided. 
The Panel further noted that the nature of the candidate substance and the proposed intended uses 
indicated by Industry suggests that the candidate substance may be a flavour precursor. The present 
evaluation of the candidate substance L-methionylglycine [FL-no: 17.037] is only applicable for its 
use in foods that are not heated or intended to be heated.  
Adequate specifications, including purity criteria and identity for the material of commerce, have 
been provided for the candidate substance.  
For the candidate substance L-methionylglycine [FL-no: 17.037] additional data are required, as no 
adequate study was available from which a NOAEL could be established.  
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
Regulation (EC) No 2232/965 of the European Parliament and the Council lays down a Procedure for 
the establishment of a list of flavouring substances the use of which will be authorised to the 
exclusion of all other substances in the EU. In application of that Regulation, a Register of flavouring 
substances used in or on foodstuffs in the Member States was adopted by Commission Decision 
1999/217/EC6, as last amended by Commission Decision 2009/163/EC7
Substances which are listed in the Register are to be evaluated according to the evaluation programme 
laid down in Commission Regulation (EC) No 1565/2000, which is broadly based on the opinion of 
the Scientific Committee on Food (SCF, 1999a).  
. Each flavouring substance is 
attributed a FLAVIS-number (FL-number) and all substances are divided into 34 chemical groups. 
Substances within a group should have some metabolic and biological behaviour in common. 
The Union list of flavourings and source materials is established in Commission Regulation (EC) No 
872/20128
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
. 
The European Commission requests the European Food Safety Authority EFSA to carry out a safety 
assessment on the flavouring substance L-methionylglycine [FL-no: 17.037], in accordance with 
Commission Regulation (EC) No 1565/2000. 
                                                     
5 Regulation No 2232/96 of the European Parliament and of the Council of 28 October 1996. Official Journal of the 
European Communities 23.11.1996, L 299, 1-4. 
6 Commission Decision 1999/217/EC of 23 February 1999 adopting a register of flavouring substances used in or on 
foodstuffs. Official Journal of the European Communities 27.3.1999, L 84, 1-137. 
7 Commission Decision 2009/163/EC of 26 February 2009 amending Decision 1999/217/EC as regards the Register of 
flavouring substances used in or on foodstuffs. Official Journal of the European Union 27.2.2009, L 55, 41. 
8 Commission implementing Regulation (EU) No 872/2012 of 1 October 2012 adopting the list of flavouring substances 
provided for by Regulation (EC) No 2232/96 of the European Parliament and of the Council, introducing it in Annex I to 
Regulation (EC) No 1334/2008 of the European Parliament and of the Council and repealing Commission Regulation 
(EC) No 1565/2000 and Commission Decision 1999/217/EC. Official Journal of the European Communities 2.10.2012, L 
267, 1-161. 
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ASSESSMENT 
1. Presentation of the Substances in Flavouring Group Evaluation 305 
1.1. Description 
The present Flavouring Group Evaluation 305 (FGE.305), using the Procedure as referred to in the 
Commission Regulation (EC) No 1565/2000 (the Procedure – shown in schematic form in Annex I of 
this FGE), deals with one flavouring substance from chemical group 34 of Annex I of Commission 
Regulation (EC) No 1565/2000.  
The flavouring substance under consideration in the present evaluation, with its chemical Register 
name, FLAVIS- (FL-), Chemical Abstract Service- (CAS-), Council of Europe- (CoE-) and Flavor and 
Extract Manufacturers Association- (FEMA-) numbers, structure and specifications is listed in Table 
3.  
The flavouring substance L-methionylglycine [FL-no: 17.037] (candidate substance) is a dipeptide 
consisting of the essential amino acid, L-methionine [FL-no: 17.027] (evaluated in FGE.26Rev1 
(EFSA, 2008b)) and the non-essential amino acid glycine [FL-no: 17.034] (evaluated by the JECFA 
and supporting substance in FGE.26Rev1). If hydrolysed, the candidate substance will yield these two 
amino acids. 
Industry has stated, in a communication of 22 February 2012 (Flavour Industry, 2012), that the 
dipeptide L-methionylglycine currently is not used as a flavouring substance, and that use figures for 
some food categories are estimates. This would imply that the production figure could change if/when 
the substance comes into use, and would further imply that the intake estimation using the MSDI 
approach, on which the current evaluation has been based, could be, or could become soon, 
superseded. 
The Panel noted that amino acids may react with other food constituent upon heating. The reaction 
mixtures formed are commonly referred to as “process flavours”, which have not been evaluated by 
the Panel. The present evaluation is therefore carried out on the basis that the flavouring substance is 
used in foods that are not intended to be heated and that it is in an unchanged form when consumed in 
food. Industry has stated that in their opinion it is justified to assume that this dipeptide will not 
change during processing, based on the fact that flavouring substances that are added to e.g. dairy 
products that are sterilised, need to be “heat stable” (Flavour Industry, 2012). No documentation has 
been submitted to underpin this assumption. As Industry has informed that the candidate substance is 
used in e.g. bakery wares, processed vegetables, soups, savouries etc., i.e. foodstuffs that presumably 
are intended to be heated, the implication is that the present evaluation may not cover all aspects of 
the intended use of the candidate flavouring substance. 
The evaluation of the candidate flavouring substance [FL-no: 17.037] is based on that it is not used in 
foods that are heated or are intended to be heated. 
A summary of the safety evaluation is summarised in Table 4. 
1.2. Stereoisomers 
It is recognised that geometrical and optical isomers of substances may have different properties. 
Their flavour may be different, they may have different chemical properties resulting in possible 
variability in their absorption, distribution, metabolism, elimination and toxicity. Thus, information 
must be provided on the configuration of the flavouring substance, i.e. whether it is one of the 
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geometrical/optical isomers, or a defined mixture of stereoisomers. The available specifications of 
purity will be considered in order to determine whether the safety evaluation carried out for candidate 
substances for which stereoisomers may exist can be applied to the material of commerce. Flavouring 
substances with different configurations should have individual chemical names and codes (CAS 
number, FLAVIS number etc.). 
The candidate substance L-methionylglycine [FL-no: 17.037] possesses one chiral centre. The optical 
isomer has been specified (Flavour Industry, 2010) (Table 3). 
1.3. Natural Occurrence in Food 
According to TNO, the candidate substance L-methionylglycine [FL-no: 17.037] has not been 
reported to occur naturally in any food items (TNO, 2010). 
Industry has stated that L-methionylglycine has been identified in cheddar cheese (unpublished 
internal analysis, no quantitative data provided) (Flavour Industry, 2010) and in porcine heart 
(Guoliang et al., 1986). From the presentation of this study it is however not possible to assess the 
validity of the statement that L-methionylglycine should be naturally present in porcine heart.  
2. Specifications 
Purity criteria for the candidate substance have been provided by the Flavour Industry (Flavour 
Industry, 2010) (Table 3). 
Judged against the requirements in Annex II of Commission Regulation (EC) No 1565/2000, this 
information is adequate for the candidate substance (see Section 1.2 and Table 3). 
3. Intake Data 
Annual production volumes of the flavouring substances as surveyed by the Industry can be used to 
calculate the “Maximised Survey-derived Daily Intake” (MSDI) by assuming that the production 
figure only represents 60 % of the use in food due to underreporting and that 10 % of the total EU 
population are consumers (SCF, 1999). 
However, the Panel noted that due to year-to-year variability in production volumes, to uncertainties 
in the underreporting correction factor and to uncertainties in the percentage of consumers, the 
reliability of intake estimates on the basis of the MSDI approach is difficult to assess. 
The Panel also noted that in contrast to the generally low per capita intake figures estimated on the 
basis of this MSDI approach, in some cases the regular consumption of products flavoured at use 
levels reported by the Flavour Industry in the submissions would result in much higher intakes. In 
such cases, the human exposure thresholds below which exposures are not considered to present a 
safety concern might be exceeded. 
Considering that the MSDI model may underestimate the intake of flavouring substances by certain 
groups of consumers, the SCF recommended also taking into account the results of other intake 
assessments (SCF, 1999). 
One of the alternatives is the “Theoretical Added Maximum Daily Intake” (TAMDI) approach, which 
is calculated on the basis of standard portions and upper use levels (SCF, 1995) for flavourable 
beverages and foods in general, with exceptional levels for particular foods. This method is regarded 
as a conservative estimate of the actual intake by most consumers because it is based on the 
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assumption that the consumer regularly eats and drinks several food products containing the same 
flavouring substance at the upper use level. 
One option to modify the TAMDI approach is to base the calculation on normal rather than upper use 
levels of the flavouring substances. This modified approach is less conservative (e.g., it may 
underestimate the intake of consumers being loyal to products flavoured at the maximum use levels 
reported). However, it is considered as a suitable tool to screen and prioritise the flavouring 
substances according to the need for refined intake data (EFSA, 2004). 
3.1. Estimated Daily per Capita Intake (MSDI Approach) 
The intake estimation is based on the Maximised Survey-derived Daily Intake (MSDI) approach, 
which involves the acquisition of data on the amounts used in food as flavourings (SCF, 1999). These 
data are derived from surveys on annual production volumes in Europe. These surveys were 
conducted in 1995 by the International Organization of the Flavour Industry, in which flavour 
manufacturers reported the total amount of each flavouring substance incorporated into food sold in 
the EU during the previous year (IOFI, 1995). The intake approach does not consider the possible 
natural occurrence in food. 
Average per capita intake (MSDI) is estimated on the assumption that the amount added to food is 
consumed by 10 % of the population9
The anticipated total annual volume of production of the candidate substance in the present 
Flavouring Group Evaluation (FGE.305) from use as flavouring substance in Europe has been 
reported to be approximately 10 kg (Flavour Industry, 2010). On the basis of the anticipated annual 
volume of production reported for the candidate substance, the estimated intake of L-
methionylglycine from use as a flavouring substance is 1.2 µg per capita per day (Table 4). 
 (Eurostat, 1998). This is derived for candidate substances from 
estimates of annual volume of production provided by Industry and incorporates a correction factor of 
0.6 to allow for incomplete reporting (60 %) in the Industry surveys (SCF, 1999). 
3.2. Intake Estimated on the Basis of the Modified TAMDI (mTAMDI) 
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values 
is based on the approach used by SCF up to 1995 (SCF, 1995). 
The assumption is that a person may consume a certain amount of flavourable foods and beverages 
per day. 
For the candidate substance information on food categories and normal and maximum use levels10,11
                                                     
9 EU figure 375 millions. This figure relates to EU population at the time for which production data are available, and is 
consistent (comparable) with evaluations conducted prior to the enlargement of the EU. No production data are available 
for the enlarged EU. 
 
was submitted by the Flavour Industry (Flavour Industry, 2010). The candidate substance is proposed 
to be used in flavoured food products divided into the food categories, outlined in Annex III of the 
Commission Regulation (EC) No 1565/2000, as shown in Table 1. For the present calculation of 
mTAMDI, the reported normal use levels were used. In the case where different use levels were 
reported for different food categories the highest reported normal use level was used. 
10 “Normal use” is defined as the average of reported usages and “maximum use” is defined as the 95th percentile of reported 
usages (EFFA, 2002). 
11 The normal and maximum use levels in different food categories (EC, 2000) have been extrapolated from figures derived 
from 12 model flavouring substances (EFFA, 2004). 
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Table 1:  Use of the Candidate Substance in Various Food Categories 
Food 
category 
Description Flavouring used 
01.0 Dairy products, excluding products of category 2 Yes 
02.0 Fats and oils, and fat emulsions (type water-in-oil) No 
03.0 Edible ices, including sherbet and sorbet No 
04.1 Processed fruits Yes 
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and 
legumes), and nuts & seeds 
Yes 
05.0 Confectionery No 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses 
& legumes, excluding bakery 
No 
07.0 Bakery wares Yes 
08.0 Meat and meat products, including poultry and game No 
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  No 
10.0 Eggs and egg products No 
11.0 Sweeteners, including honey No 
12.0 Salts, spices, soups, sauces, salads, protein products etc. Yes 
13.0 Foodstuffs intended for particular nutritional uses No 
14.1 Non-alcoholic ("soft") beverages, excl. dairy products No 
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts No 
15.0 Ready-to-eat savouries Yes 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not 
be placed in categories 1 – 15 
No 
 
According to the Flavour Industry the normal use level for the candidate substance is in the range of 
50 - 150 mg/kg food and the maximum use level is in the range of 1000 - 3000 mg/kg (Flavour 
Industry, 2010) (see Table II.1.2, Annex II). The mTAMDI value is 24000 µg/person/day (see Section 
5).  
4. Absorption, distribution, metabolism and elimination 
No studies have been provided for the absorption, distribution, metabolism and excretion (ADME) of 
the candidate substance L-methionylglycine [FL-no: 17.037], a dipeptide. There is no information as 
to whether the dipeptide is absorbed intact or not, or regarding its fate or potential adverse biological 
activities if it is absorbed in intact form. 
Di- and tripeptides may be absorbed rapidly and effectively from the intestinal canal, and transport of 
amino acids in the form of small peptides may be a faster route of uptake than that of the amino acids 
in free form. In humans, two di- and tripeptide transporters have been identified, human peptide 
transporter 1 and 2. Peptides may also be absorbed intact via other mechanisms such as by passive 
diffusion, paracellular route, endocytosis or carrier mediated transport. Proteins and peptides may be 
transported from the intestinal lumen to the blood circulation in biologically significant amounts. Di- 
and tripeptides are prone to be systemically distributed. Composition of dietary protein may affect the 
levels of circulating peptides. A study (Matthews and Webb, 1995) showed that the candidate 
substance L-methionylglycine [FL-no: 17.037] is transferred intact through two types of sheep 
epithelial tissue in vitro. 
Dipeptides can be hydrolysed to component amino acids by several peptidases present in several 
organs, but rate and extent of hydrolysis may vary considerably, and there are great differences in the 
rate of hydrolysis of small peptides.  
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Research on oral availability of bioactive peptides is gaining attention, and several studies show that 
peptides may be absorbed intact with retained biological activity after oral administration. In a study 
on rats designed to determine the effect of amino acid chain length on the ability of enterally 
administered peptides to produce biological effects, the results showed that the shorter the amino acid 
chain length the more bioactivity was retained. E.g. the tripeptide thyrotropin releasing hormone had 
the same effect when administered enterally as when administered intravenously (Roberts et al., 
1999). 
If hydrolysed, the dipeptide L-methionylglycine will generate the two amino acids methionine and 
glycine, components of dietary protein. Methionine and glycine are metabolised to innocuous 
products when ingested at amounts that occur naturally in the diet. However, methionine can be 
converted via de-methylation to homocysteine. High intakes of single amino acids may lead to amino 
acid imbalances that may affect uptake, metabolism pathways and mechanisms of transport etc. 
Without information about the potential for hydrolysis of the candidate substance L-methionylglycine 
[FL-no: 17.037] and without any studies that show the fate of the substance in vitro and/or in vivo, it 
is not possible to predict whether it will be absorbed as a dipeptide or not, nor its distribution or 
immediate fate after absorption, e.g. if there is any tissue specific availability or specificity for 
utilization of this dipeptide. Since such information is lacking, rapid metabolism of the dipeptide to 
innocuous metabolites cannot be anticipated. 
For more detailed information, see Annex III. 
5. Application of the Procedure for the Safety Evaluation of Flavouring Substances 
The application of the Procedure is based on intakes estimated on the basis of the MSDI approach. 
Where the mTAMDI approach indicates that the intake of a flavouring substance might exceed its 
corresponding threshold of concern, a formal safety assessment is not carried out using the Procedure. 
In these cases the Panel requires more precise data on use and use levels. For comparison of the intake 
estimations based on the MSDI approach and the mTAMDI approach, see Section 6. 
The present evaluation of the flavouring candidate substance L-methionylglycine [FL-no: 17.037] is 
based on the assumption that it is not used in foods that are heated or are intended to be heated. 
The candidate substance L-methionylglycine [FL-no: 17.037] is classified according to the decision 
tree approach by Cramer et al. into structural class III (Cramer et al., 1978). 
Step 1 
Step 2 requires consideration of the metabolism of the candidate substance. No information has been 
provided on hydrolysis of the candidate substance [FL-no: 17.037] under physiological conditions, 
Without information about the potential for hydrolysis of the candidate substance L-methionylglycine 
[FL-no: 17.037] and without any studies that show the fate of the substance in vitro and/or in vivo, it 
is not possible to predict whether it will be absorbed as a dipeptide or not, nor to its distribution or 
potential bioactivity after absorption. Since such information is lacking, rapid metabolism of the 
dipeptide to innocuous metabolites cannot be anticipated. The candidate substance will subsequently 
proceed via the B-side of the Procedure.  
Step 2 
The estimated daily per capita intake of the candidate substance [FL-no: 17.037] is 1.2 µg according 
to the MSDI approach. This is below the threshold for structural class III of 90 µg/person/day.  
Step B3 
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No adequate study from which a NOAEL could be established was available. Therefore the Panel 
concluded that additional data are required for the candidate substance L-methionylglycine [FL-no: 
17.037]. 
Step B4 
6. Comparison of the Intake Estimations Based on the MSDI Approach and the 
mTAMDI Approach 
The estimated intake of the substance [FL-no: 17.037] assigned to structural class III, based on the 
mTAMDI, is 24000 µg/person/day, which is above the threshold of concern for structural class III of 
90 µg/person/day. According to the Flavour Industry the normal use level for the candidate substance 
is in the range of 50 - 150 mg/kg food and the maximum use level is in the range of 1000 - 3000 
mg/kg. 
The Panel noted the large differences in the MSDI and mTAMDI figures. See Table 2. 
Since the candidate substance has not yet come into use, the anticipated annual production volume for 
use as flavouring substance in Europe does not reflect the actual state of use of the candidate 
substance. The reported use levels for this substance indicate that the actual use may lead to high 
intake figures. This is reflected by the very large discrepancy between the intake estimations 
according to the MSDI and mTAMDI approach. 
Table 2:  Estimated intakes based on the MSDI approach and the mTAMDI approach 
FL-no EU Register name MSDI 
(µg/capita/day) 
mTAMDI 
(µg/person/day) 
Structural 
class 
Threshold of concern 
(µg/person/day) 
17.037 L-Methionylglycine 1.2 24000 Class III 90 
7. Considerations of Combined Intakes from Use as Flavouring Substances 
Because of structural similarities of candidate and supporting substances, it can be anticipated that 
many of the flavourings are metabolised through the same metabolic pathways and that the 
metabolites may affect the same target organs. Further, in case of combined exposure to structurally 
related flavourings, the pathways could be overloaded. Therefore, combined intake should be 
considered. As flavourings not included in this FGE may also be metabolised through the same 
pathways, the combined intake estimates presented here are only preliminary. Currently, the 
combined intake estimates are only based on MSDI exposure estimates, although it is recognised that 
this may lead to underestimation of exposure. After completion of all FGEs, this issue should be 
readdressed. 
The total estimated combined daily per capita intake of structurally related flavourings is estimated 
by summing the MSDI for individual substances. 
Considerations of combined intakes are not applicable in this evaluation. 
8. Toxicity 
General information and specific studies 
Peptides as well as single amino acids may have adverse biological activities. 
Bioactive peptides usually contain between 2 and 20 amino acids, these peptides may be derived from 
food proteins or may be produced by processing food or produced synthetically (Vermeirssen et al., 
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2004). Bioactive peptides have lately gained much interest as dietary components with beneficial or 
detrimental health potentials, and as substances that may be used for biomedical applications and for 
development of medicinal drugs. Oral bioavailability of bioactive peptides may vary greatly. In 
general the shorter the amino acid chain, the greater the probability of the peptide being absorbed 
intact with retained bioactivity. 
For di- and higher peptides selective toxicity may affect specific physiological processes. Zaloga and 
Siddiqui reviewed some dietary peptides with biological activity (Zaloga and Siddiqui, 2004). In this 
review it is stated that: “Importantly, many dietary peptides are biologically so potent that even small 
amounts entering the circulation could have major pathophysiological significance. These peptides 
may produce their affects in the body at concentrations of micrograms to milligrams per mL. Since 
human adults absorb approximately 100 g protein per day (i.e. 1 - 1.5 g/kg), only a small fraction of 
ingested protein need be absorbed [as biologically active protein or peptides] to produce systemic 
effects.” Some examples of dietary peptides with bioactivity that are mentioned are peptides derived 
from casein or soy proteins that modulate immune function, e.g. methionine-enkephalin, a 
pentapeptide.  
Among others, the following examples of bioactive peptides with retained oral activity may be 
mentioned. Pepsin digests from tuna inhibit angiotensin-I converting enzyme (ACE) and oral 
administration of digests significantly reduced blood pressure of rats. In this study (Astawan et al., 
1995), four inhibitor peptides were found, two penta- and two hexapeptides ACE-inhibitory peptides 
may be produced in fermented milk, and two such tripeptides have been shown to be absorbed intact 
with retained bioactivity in rats and fermented milk containing the tripeptides had blood pressure 
reducing activity when administered orally to humans (Masuda et al., 1996; Seppo et al., 2003). The 
hypoglycemic dipeptide cyclo His-Pro, that may be found in different food items, has oral 
bioavailability with retained bioactivity (Hilton et al., 1990; Choi et al., 2013). 
L-Methionylglycine [FL-no: 17.037] 
For the candidate substance no reliable information has been made available or found in a literature 
search. 
There is one in vitro study published on physiological effects of the candidate substance. The object 
was to look for endogenous peptides with activity on heart muscle. L-Methionylglycine was isolated 
from porcine heart (as referred in Section 1.3.). When this dipeptide was tested on cultured 
myocardial cells from rat, the beating rate of the cells increased about 30 % (Guoliang et al., 1986). 
However, from the presentation of the study it is not possible to assess the validity of these 
observations. 
Methionine 
Overload of a single amino acid, e.g. L-methionine, may lead to amino acid imbalance resulting in 
toxicity.  
Any toxic effects of methionine may be accounted for by metabolites, i.e. homocysteine (Toue et al., 
2006; Hanratty et al., 2001). Homocysteine has been implicated in cardiovascular, hepatic and 
cognitive disease (IOM, 2002). 
Amino acid composition of the proteins may have effect on plasma cholesterol levels. Reports suggest 
that dietary proteins with low ratios of methionine-glycine and lysine-arginine favor a 
hypocholesterolemic effect, and that e.g. bovine casein tends to elevate plasma cholesterol levels due 
to its high ratios of methionine-glycine and lysine-arginine (Morita et al., 1997; Erdmann et al., 2008). 
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Daily dietary intake of methionine is approximately 1.4 g for a person consuming 100 g protein per 
day. 
So far, in spite of efforts made, no upper level has been established for methionine due to lack of 
dose-response data. The ANS-panel considered an addition to the diet of 57.2 mg methionine/day, 
corresponding to about 0,95 mg methionine/kg body weight/day, to be negligible compared to the 
normal dietary intake (EFSA, 2008a). The mTAMDI value for L-methionylglycine [FL-no: 17.037] is 
24 mg/person/day, as shown in Section 6. This corresponds to about 17.4 mg methionine.  
Conclusion 
Both single amino acids and peptides may have adverse biological activities. Some dietary peptides 
have great potency and may exert effects at concentrations ranging from µg – mg/mL plasma. If the 
candidate substance L-methionylglycine [FL-no: 17.037] is absorbed intact there is no data on the fate 
of the substance or its potential adverse biological activity and potency. 
8.1. Acute Toxicity 
No data are available for the candidate substance, L-methionylglycine [FL-no: 17.037]. 
8.2. Subacute, Subchronic, Chronic and Carcinogenicity Studies 
Subacute and subchronic toxicity data are not available for the candidate substance, L-
methionylglycine [FL-no: 17.037]. 
8.3. Developmental / Reproductive Toxicity Studies 
No data on developmental toxicity and reproductive toxicity are available for the candidate substance, 
L-methionylglycine [FL-no: 17.037]. 
8.4. Genotoxicity Studies 
No in vitro or in vivo genotoxicity data are available for the candidate substance, L-methionylglycine 
[FL-no: 17.037]. 
Conclusion on Genotoxicity 
No data on genotoxicity has been submitted for the candidate substance; however, consideration of 
the chemical structure does not give rise to safety concern with respect to genotoxicity. 
CONCLUSIONS 
The FGE.305 deals with the evaluation of one candidate substance, the dipeptide L-methionylglycine 
[FL-no: 17.037].  
The candidate substance possesses one chiral centre and the optical isomer has been specified. It 
belongs to structural class III and has not been reported to occur naturally in any food items according 
to TNO.  
According to the default MSDI approach the intake in Europe for the candidate substance [FL-no: 
17.037] is 1.2 µg/capita/day. 
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No data on genotoxicity has been submitted for the candidate substance. However, consideration of 
the chemical structure does not give rise to safety concern with respect to genotoxicity. 
No information has been provided on hydrolysis of the candidate substance [FL-no: 17.037] under 
physiological conditions. Without information about the potential for hydrolysis of the candidate 
substance L-methionylglycine [FL-no: 17.037] and without any studies that show the fate of the 
substance in vitro and/or in vivo, it is not possible to predict whether it will be absorbed as a dipeptide 
or not, nor its distribution or potential bioactivity after absorption. Since such information is lacking, 
rapid metabolism of the dipeptide to innocuous metabolites cannot be anticipated. Therefore, 
evaluation of the candidate substance proceeds via the B-side to step B4 of the Procedure, at which 
step no adequate study from which a No Observed Adverse Effect Level (NOAEL) was available. So, 
the Panel concluded that additional data are required for the candidate dipeptide L-methionylglycine 
[FL-no: 17.037]. 
When the estimated intake was based on the mTAMDI, it was 24000 µg/person/day, which is above 
the threshold for structural class III of 90 µg/person/day.  
The Panel noted the high discrepancy between MSDI and mTAMDI. The hypothetical nature of the 
MSDI, which is based on anticipated volumes of production, leads to a high uncertainty in the safety 
evaluation of this substance when based on the MSDI. The Panel will therefore not be in a position to 
conclude on the absence of safety concern for this specific substance unless a more refined dietary 
exposure estimate based on use levels is provided. 
The Panel further noted that the nature of the candidate substance and the proposed intended uses 
indicated by Industry suggests that the candidate substance may be a flavour precursor. The present 
evaluation of the candidate substance L-methionylglycine [FL-no: 17.037] is only applicable for its 
use in foods that are not heated or intended to be heated.  
Adequate specifications, including purity criteria and identity for the material of commerce, have 
been provided for the candidate substance.  
For the candidate substance L-methionylglycine [FL-no: 17.037] additional data are required, as no 
adequate study was available from which a NOAEL could be established.  
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Table 3:  Specification Summary of the Substances in the Flavouring Group Evaluation 305 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
Specification comments 
17.037 
 
L-Methionylglycine 
OH
H
N
S
O
O
NH2
 
4692 
 
14486-03-4 
Solid 
C7H14N2O3S 
206.27 
Soluble 
Soluble 
 
201 
MS 
98 % 
n.a. 
n.a. 
 
 
1) Solubility in water, if not otherwise stated. 
2) Solubility in 95 %  ethanol, if not otherwise stated. 
3) At 1013.25 hPa, if not otherwise stated. 
4) At 20°C, if not otherwise stated. 
5) At 25°C, if not otherwise stated. 
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Table 4:  Summary of Safety Evaluation Applying the Procedure (Based on Intakes Calculated by the MSDI Approach) 
FL-no EU Register name Structural formula MSDI 1) 
(µg/capita/day) 
Class 2) 
Evaluation procedure path 3) 
Outcome on the named 
compound 
[ 4) or 5)] 
Outcome on the material of 
commerce [6), 7), or 8)] 
Evaluation remarks 
17.037 
 
L-Methionylglycine 
OH
H
N
S
O
O
NH2
 
1.2 
 
Class III 
B3: Intake below threshold,  
B4: No adequate NOAEL 
Additional data required 6)  
1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
3) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
6) No safety concern at estimated level of intake of the material of commerce meeting the specification of Table 3 (based on intake calculated by the MSDI approach). 
7) Tentatively regarded as presenting no safety concern (based on intake calculated by the MSDI approach) pending further information on the purity of the material of commerce and/or information on stereoisomerism. 
8) No conclusion can be drawn due to lack of information on the purity of the material of commerce. 
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ANNEXES 
ANNEX I: PROCEDURE FOR THE SAFETY EVALUATION 
The approach for a safety evaluation of chemically defined flavouring substances as referred to in 
Commission Regulation (EC) No 1565/2000, named the "Procedure", is shown in schematic form in 
Figure I.1. The Procedure is based on the opinion of the Scientific Committee on Food expressed on 2 
December 1999 (SCF, 1999), which is derived from the evaluation Procedure developed by the Joint 
FAO/WHO Expert Committee on Food Additives at its 44th, 46th and 49th meetings (JECFA, 1995; 
JECFA, 1996; JECFA, 1997; JECFA, 1999). 
The Procedure is a stepwise approach that integrates information on intake from current uses, 
structure-activity relationships, metabolism and, when needed, toxicity. One of the key elements in 
the Procedure is the subdivision of flavourings into three structural classes (I, II, III) for which 
thresholds of concern (human exposure thresholds) have been specified. Exposures below these 
thresholds are not considered to present a safety concern. 
Class I contains flavourings that have simple chemical structures and efficient modes of metabolism, 
which would suggest a low order of oral toxicity. Class II contains flavourings that have structural 
features that are less innocuous, but are not suggestive of toxicity. Class III comprises flavourings that 
have structural features that permit no strong initial presumption of safety, or may even suggest 
significant toxicity (Cramer et al., 1978). The thresholds of concern for these structural classes of 
1800, 540 or 90 µg/person/day, respectively, are derived from a large database containing data on 
subchronic and chronic animal studies (JECFA, 1996). 
In Step 1 of the Procedure, the flavourings are assigned to one of the structural classes. The further 
steps address the following questions: 
• can the flavourings be predicted to be metabolised to innocuous products12
• do their exposures exceed the threshold of concern for the structural class (Step A3 and B3)? 
 (Step 2)?  
• are the flavourings or their metabolites endogenous13
• does a NOAEL exist on the flavourings or on structurally related substances (Step A5 and 
B4)? 
 (Step A4)?  
In addition to the data provided for the flavouring substances to be evaluated (candidate substances), 
toxicological background information available for compounds structurally related to the candidate 
substances is considered (supporting substances), in order to assure that these data are consistent with 
the results obtained after application of the Procedure.  
The Procedure is not to be applied to flavourings with existing unresolved problems of toxicity. 
Therefore, the right is reserved to use alternative approaches if data on specific flavourings warranted 
such actions. 
                                                     
12 “Innocuous metabolic products”: Products that are known or readily predicted to be harmless to humans at the estimated 
intakes of the flavouring agent” (JECFA, 1997). 
13 “Endogenous substances”: Intermediary metabolites normally present in human tissues and fluids, whether free or 
conjugated; hormones and other substances with biochemical or physiological regulatory functions are not included 
(JECFA, 1997). 
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Decision tree structural class 
Can the substance be predicted to be metabolised to innocuous products? 
Procedure for Safety Evaluation of Chemically Defined Flavouring Substances 
Do the conditions of use result in an intake greater than the  
threshold of concern for the structural class? 
Do the conditions of use result in an intake greater than the  
threshold of concern for the structural class? 
Data must be available on the  
substance or closely related  
substances to perform a safety  
evaluation 
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for structurally related substances which is high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
 
 
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for structurally related substances which is high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
 
 
 
 
  Substance would not be    
expected to be of safety concern Is the substance or are its metabolites endogenous? 
Additional data required 
Step 1. 
Step 2. 
Step A3. 
Step A4. 
Step A5. 
Step B3. 
Step B4. 
 Yes  No 
 Yes 
 No 
No 
No 
Yes 
No 
Yes 
Yes 
Yes 
 No 
1 
Figure I.1 Procedure for Safety Evaluation of Chemically Defined Flavouring Substances2 
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ANNEX II: USE LEVELS / MTAMDI 
II.1 Normal and Maximum Use Levels 
For each of the 18 Food categories (Table II.1.1) in which the candidate substance is used, Flavour 
Industry reports a “normal use level” and a “maximum use level”. According to the Industry the 
”normal use” is defined as the average of reported usages and ”maximum use” is defined as the 95th 
percentile of reported usages (EFFA, 2002). The normal and maximum use levels in different food 
categories have been extrapolated from figures derived from 12 model flavouring substances (EFFA, 
2004). 
Table II.1.1 Food categories according to Commission Regulation (EC) No 1565/2000  
Food category Description 
01.0 Dairy products, excluding products of category 02.0 
02.0 Fats and oils, and fat emulsions (type water-in-oil) 
03.0 Edible ices, including sherbet and sorbet 
04.1 Processed fruit 
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and legumes), and nuts & seeds 
05.0 Confectionery 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & legumes, excluding bakery 
07.0 Bakery wares 
08.0 Meat and meat products, including poultry and game 
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  
10.0 Eggs and egg products 
11.0 Sweeteners, including honey 
12.0 Salts, spices, soups, sauces, salads, protein products, etc. 
13.0 Foodstuffs intended for particular nutritional uses 
14.1 Non-alcoholic ("soft") beverages, excl. dairy products 
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts 
15.0 Ready-to-eat savouries 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be placed in categories 01.0 - 15.0 
 
The “normal and maximum use levels” are provided by Industry (Flavour Industry, 2010) for the 
candidate substance in the present flavouring group (Table II.1.2). 
Table II.1.2 Normal and Maximum use levels (mg/kg) for the candidate substances in FGE.305 (Flavour 
Industry, 2010). 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
17.037 150 
3000 
- 
- 
- 
- 
50 
1000 
50 
1000 
- 
- 
- 
- 
50 
1000 
- 
- 
- 
- 
- 
- 
- 
- 
100 
2000 
- 
- 
- 
- 
- 
- 
100 
2000 
- 
- 
II.2 mTAMDI Calculations 
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values 
is based on the approach used by SCF up to 1995 (SCF, 1995). The assumption is that a person may 
consume the amount of flavourable foods and beverages listed in Table II.2.1. These consumption 
estimates are then multiplied by the reported use levels in the different food categories and summed 
up. 
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Table II.2.1 Estimated amount of flavourable foods, beverages, and exceptions assumed to be consumed per 
person per day (SCF, 1995) 
Class of product category Intake estimate (g/day) 
Beverages (non-alcoholic) 324.0 
Foods 133.4 
Exception a: Candy, confectionery 27.0 
Exception b: Condiments, seasonings 20.0 
Exception c: Alcoholic beverages 20.0 
Exception d: Soups, savouries 20.0 
Exception e: Others, e.g. chewing gum e.g. 2.0 (chewing gum) 
 
The mTAMDI calculations are based on the normal use levels reported by Industry. The seven food 
categories used in the SCF TAMDI approach (SCF, 1995) correspond to the 18 food categories as 
outlined in Commission Regulation (EC) No 1565/2000 and reported by the Flavour Industry in the 
following way (see Table II.2.2): 
• Beverages (SCF, 1995) correspond to food category 14.1  
• Foods (SCF, 1995) correspond to the food categories 1, 2, 3, 4.1, 4.2, 6, 7, 8, 9, 10, 13, and/or 
16  
• Exception a (SCF, 1995) corresponds to food category 5 and 11  
• Exception b (SCF, 1995) corresponds to food category 15  
• Exception c (SCF, 1995) corresponds to food category 14.2  
• Exception d (SCF, 1995) corresponds to food category 12  
• Exception e (SCF, 1995) corresponds to others, e.g. chewing gum. 
 
Table II.2.2 Distribution of the 18 food categories listed in Commission Regulation (EC) No 1565/2000 into 
the seven SCF food categories used for TAMDI calculation (SCF, 1995) 
 Food categories according to Commission Regulation (EC) No1565/2000 Distribution of the seven SCF food categories 
Key Food category Food Beverages Exceptions 
01.0 Dairy products, excluding products of category 02.0 Food   
02.0 Fats and oils, and fat emulsions (type water-in-oil) Food   
03.0 Edible ices, including sherbet and sorbet Food   
04.1 Processed fruit Food   
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and legumes), 
and nuts & seeds 
Food   
05.0 Confectionery   Exception a 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & 
legumes, excluding bakery 
Food   
07.0 Bakery wares Food   
08.0 Meat and meat products, including poultry and game Food   
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  Food   
10.0 Eggs and egg products Food   
11.0 Sweeteners, including honey   Exception a 
12.0 Salts, spices, soups, sauces, salads, protein products, etc.    Exception d 
13.0 Foodstuffs intended for particular nutritional uses Food   
14.1 Non-alcoholic ("soft") beverages, excl. dairy products  Beverages  
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Table II.2.2 Distribution of the 18 food categories listed in Commission Regulation (EC) No 1565/2000 into 
the seven SCF food categories used for TAMDI calculation (SCF, 1995) 
 Food categories according to Commission Regulation (EC) No1565/2000 Distribution of the seven SCF food categories 
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts   Exception c 
15.0 Ready-to-eat savouries   Exception b 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be placed 
in categories 01.0 - 15.0 
Food   
 
The mTAMDI value (see Table II.2.3) is presented for the flavouring substance in the present 
flavouring group, for which Industry has provided use and use levels (Flavour Industry, 2010). The 
mTAMDI value is only given for the highest reported normal use level. 
TableII.2.3 Estimated intakes based on the mTAMDI approach 
FL-no EU Register name mTAMDI 
(µg/person/day) 
Structural class Threshold of concern 
(µg/person/day) 
17.037 L-Methionylglycine 24000 Class III 90 
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ANNEX III: METABOLISM 
III.1. Introduction 
The present FGE consists of one candidate substance, a dipeptide, L-methionylglycine [FL-no: 
17.037].  
N
OHS
NH2
H
O
O
 
L-Methionine and glycine belong to the group of twenty amino acids which are normal components of 
food proteins. L-Methionine is considered an essential amino acid for humans since it has to be 
provided by the diet and cannot be synthesised within the body. Protein intake in humans in the 
western world is estimated to be around 100 g/person/day (1 - 1.5 g/kg body weight) (Zaloga and 
Siddiqui, 2004). The requirement for methionine in the diet for mammals is considered to be 0.5 - 0.6 
% of the diet (Yamada et al., 2012). For humans, dietary requirement for sulphur containing amino 
acids is 13 - 16 mg/kg body weight (bw)/day equivalent to 17 - 27 mg/g protein, but how much of this 
that can be methionine relative to cysteine is still controversial. Glycine is a non-essential amino acid, 
and out of the 20 amino acids that are building blocks of proteins, it is the only one that does not 
contain an asymmetrical carbon. The dipeptide L-methionylglycine [FL-no: 17.037] is however not 
reported to occur naturally in any food items according to TNO (TNO, 2010). According to an 
unpublished internal analysis with no quantitative data provided, Industry has informed that L-
methionylglycine has been identified in cheddar cheese (Flavour Industry, 2010), and also in porcine 
heart (Guoliang et al., 1986), the validity of this study is however not possible to assess due to 
limitations in the study report, and lack of information on study design and execution.  
III.2. Absorption, Distribution and Elimination 
No studies on absorption, distribution or elimination of the candidate substance have been provided.  
Proteins are digested in the low pH of the stomach by pepsin. In the more alkaline pH of the small 
intestine, pancreatic proteases further digest and cleave proteins and polypeptides resulting in 
oligopeptides and to a lesser extent of free amino acids. Free amino acids are absorbed into 
enterocytes via amino acid transport systems. Oligopeptides are further hydrolysed via brush border 
peptidases, mainly resulting in free amino acids and di- and tripeptides. Single amino acids are 
directly available for absorption by the small intestine and appear in the portal vein more rapidly than 
amino acids that are parts of proteins, e.g. intake of protein hydrolysates increased plasma levels of 
Val-Leu to a significantly greater extent than did ingestion of whole protein (Morifuji et al., 2010). 
Di- and tripeptides may be absorbed rapidly and effectively in the intestinal canal and transport of 
amino acids in the form of small peptides may be a faster route of uptake than that of the amino acids 
in free form (Webb, 1990; Erdmann et al., 2008). In humans, two di- and tripeptide transporters have 
been identified, human peptide transporter 1 and 2 (PepT1 and PepT2). The peptide transporter PepT1 
can potentially transport all 400 dipeptides that may result as combinations of the 20 dietary amino 
acids. Di- and tripeptides have the capability to be, and may be prone to be, systematically distributed 
and may reach specific organs and tissues by transport via PepT1 and 2 (Santos et al., 2012). Peptides 
may also be absorbed intact via other mechanisms such as by passive diffusion, via paracellular route, 
via endocytosis or via carrier mediated transport (Vermeirssen et al., 2004). Intact proteins and 
peptides may be transported from the intestinal lumen to the blood circulation in biologically 
significant amounts (Gardner, 1988; Vermeirssen et al., 2004). According to Grimble (1994) as cited 
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by Zaloga and Siddiqui (Zaloga and Siddiqui, 2004) - 20 % of plasma amino acids are present as 
peptides. 
Dipeptides can be hydrolysed by several peptidases present in several organs, but rate and extent of 
hydrolysis may vary greatly. As an illustration, in a study from 1960 (Johnston and Wiggans, 1960) 
the enzymatic breakdown of 15 peptides during 8 - 120 minutes was studied using peritoneal fluid 
from rats and humans, and a wide range of specificity was observed. Whereas e.g. L-leucyl-L-alanine 
was extensively hydrolysed after 8 minutes, e.g. glycylglycine was only slightly hydrolysed after 120 
minutes, which was the length of the study. This study indicates great differences in the rate of 
hydrolysis of small peptides.  
Data suggests that diet influences concentrations of circulating dipeptides and their availability to 
extrahepatic tissues. Tissue selectivity for peptide removal has been shown, which suggests that there 
may be tissue specific abilities to utilize circulating plasma peptides (Gilbert et al., 2008). For L-
methionine-containing peptides the molecular structure influences the availability of the essential 
amino acid methionine. Methionine-containing peptides were utilized differently by three different 
cell types, implicating that there may be cell-specific differences in transport of small peptides, as 
well as in hydrolytic events (Gilbert et al., 2008; Pan and Webb, 1998). 
The knowledge that some peptides are resistant to hydrolysis, and the finding of a peptide transporter 
in the basolateral membrane of enterocytes suggests that there may be a carrier-mediated mechanism 
for transport of peptides to the bloodstream (Terada et al., 1999). In mice the uptake of carnosine 
(beta-alaninehistidine), a dipeptide found in high amounts in muscle tissue, was found to be equally 
stimulated by high dietary levels of amino acids, peptides or proteins. Hydrolysis of carnosine was 
low or negligible (Ferraris et al., 1988).  
N
NH
OH
O
N
O
HH2N
  Carnosine (beta-alaninehistidine) 
Bioactive peptides are peptides, which may be derived from food proteins, are inactive when 
contained in the original protein, but have bioactivity as peptides. Bioactive peptides usually contain 
between 2 and 20 amino acids (Vermeirssen et al., 2004). Bioactive peptides have lately gained much 
interest as dietary components with beneficial or detrimental health potentials, as well as for 
biomedical applications and for development of medicinal drugs. An effect of this interest is that 
research on oral availability of bioactive peptides is gaining attention. In general, even though larger 
peptides may be absorbed orally and retain biological effects the potency of peptides decreases as the 
chain length increases (Erdmann et al., 2008). E.g. in a study designed to determine the effect of 
amino acid chain length on the ability of enterally administered peptides to produce biological effects, 
rats were administered biologically active peptides enterally and intravenously. The administered 
amount was less than 0.5 % of a rat’s normal daily protein intake. The results indicated that 125 and 
500 µg enteral administered thyrotropin-releasing hormone (a tripeptide) produced the same thyroid 
stimulating hormone-effect as when administered intravenously, the response of follicle stimulating 
hormone to 500 µg enteral luteinizing hormone-releasing hormone (a decapeptide) was 50 % of the 
same hormone administered intravenously, and that the glucose response to 25 mg enteral insulin (a 
51-amino acid peptide) was 30 % of the response to 0.5 mg intravenous insulin. Both 0.5 and 25 mg 
enteral insulin significantly increased serum insulin levels (Roberts et al., 1999). 
Angiotensin I converting enzyme (ACE) has a role in regulating blood pressure as it converts 
angiotensin I to angiotensin II, which is a potent vasoconstrictor, it also inactivates the vasodilator 
bradykinin. ACE inhibitors are used as antihypertensive drugs. Lately, different food proteins have 
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been identified as sources of ACE-inhibitory peptides, and there is on-going research on 
bioavailability and effectiveness of some of these peptides. Most ACE-inhibitory peptides consist of 2 
- 9 amino acids. Two ACE-inhibitory tripeptides with blood pressure lowering effects (Val-Pro-Pro 
and Ile-Pro-Pro) produced by fermentation of milk by Lactobacillus helveticus and Saccharomyces 
cerevisiae (Calpis sour milk) were shown to decrease ACE activity and to be present in the aorta after 
a single oral administration of Calpis sour milk to spontaneously hypertensive rats (Masuda et al., 
1996). In a 21 weeks study, hypertensive human subjects received 150 mL per day of either milk 
fermented by Lactobacillus helveticus standardised to contain the ACE-inhibitory peptides Val-Pro-
Pro (2 mg/100 g product) and Ile-Pro-Pro (1.5 mg/100 g product) or a control milk fermented by a 
normal fermentation process with a Lactococcus sp. mixed culture. There was a mean difference of 
6.7 + 3.0 mmHg in systolic blood pressure and of 3.6 + 1.9 in diastolic blood pressure between test 
product group and control group, indicating that the bioactive ACE-inhibiting peptides were absorbed 
intact. Other factors that might contribute to the blood pressure lowering effect might have been 
higher calcium content of test product compared to control and inclusion of live starter bacteria in the 
test product (Seppo et al., 2003). Oral bioavailability of bioactive peptides and difficulties to assess 
how much of a bioactive peptide that is absorbed intact, is a problem when using peptides for 
biomedical purposes and in drug development, as absorption of intact peptides may vary greatly. 
However, as the above examples show, small bioactive peptides may be absorbed intact and may exert 
biological activity. 
L-Methionylglycine 
In a search in the published literature not much data may be found concerning the candidate 
substance. L-Methionylglycine was shown to be transferred intact through two types of sheep 
epithelial tissue (Matthews and Webb, 1995), suggesting that the dipeptide has a potential to be 
absorbed in intact form.  
Dipeptides with L-methionine at the N-terminal were shown to be utilised as a methionine source by 
cultured cells to a greater extent than peptides with L-methionine at the C-terminal (Pan et al., 1996). 
Without information about the potential for hydrolysis of the candidate substance and lacking studies 
that show the fate of the substance in vitro or in vivo, it is not possible to predict whether it will be 
absorbed as a dipeptide or not, nor its possible fate if absorbed as a dipeptide.  
Peptides administered orally may be absorbed intact and may have bioactivity, in general the longer 
the amino acid chain is the more of inherent bioactivity is lost during absorption. Small peptides such 
as di- and tripeptides are prone to be absorbed intact and distributed systemically.  
In healthy adults, concentrations of amino acids in plasma are maintained in a relatively steady 
manner. In general, ingestion of single amino acids may create a transient imbalance of amino acids in 
the systemic circulation. Excess amino acids may lead to adverse effects due to imbalance of amino 
acid-status or antagonism among amino acids. Antagonism may occur among amino acids that are 
related, structurally or chemically. 
III.3. Metabolism 
If absorbed as such, there is no information on the specific fate of the dipeptide L-methionylglycine, 
whether the dipeptide itself exerts any specific adverse biological activity or not, nor if there is any 
tissue specific availability or specificity for utilization of this dipeptide. In an article that Industry has 
provided on natural occurrence of L-methionylglycine (Guoliang et al., 1986) it is stated that the 
dipeptide occurs in porcine heart, and also that the dipeptide has an effect on rat myocardial cells in 
vitro by increasing the beating rate by about 30 %. However, from the presentation of the study it is 
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not possible to evaluate the validity of the study, neither as to the natural presence of the dipeptide nor 
to its potential cardioactivity. 
Glycine 
Metabolism of glycine is closely linked to that of serine. The major pathway for glycine catabolism is 
catalysed by glycine cleavage complex in liver mitochondria:  
Glycine + tetrahydrofolate + NAD+ → CO2 + NH4+ + N5,N10-Methylene tetrahydrofolate + NADH + 
H+ 
Glycine may also be converted by transamination or oxidative deamination to glyoxylic acid, which is 
further metabolised oxalate and to formic acid. Another pathway for glycine is to be transformed to 
serine through a reversible reaction catalysed by serine hydroxymethyltransferase. L-Serine formed by 
this reaction may then form pyruvate and subsequently acetyl-CoA.  
Glycine can be used to synthesise active one-carbon units, which are fragments activated by binding 
to tetrahydrofolic acid, or more seldom to thiamine pyrophosphate. Since glycine is one of the amino 
acids that participate in one-carbon metabolism and through this to methylation of proteins and DNA, 
it thereby participates in regulation of gene expression and biological activity of proteins (Wu, 2009).  
L-Methionine 
Methionine may be degraded via demethylation and transsulphuration or via transamination.  
Methylation and transsulphuration pathway: 
                                                                                                              ↗ transfer of –CH3 to other 
compounds 
Methionine + ATP → S-Adenosylmethionine + PPi + Pi → S-Adenosylhomocysteine → 
 
             H2O ↘    ↗ Adenosine        Serine↘ ↗H2O                 H2O↘ 
                     →     Homocysteine        →       Cystathione    → Cysteine + α-Ketobutyrate 
The initial step is activation to S-adenosylmethionine via ATP. S-Adenosylmethionine is a major 
donor of methyl groups, which with loss of the methyl group is converted to S-adenosylhomocysteine 
and sequently metabolised to homocysteine, combined with serine to yield cystathionine which may 
undergo further metabolism to cysteine, ammonia and alpha-ketobutyrate.  
L-Cysteine can form taurine and CO2, or sulphate, urea and CO2. alpha-Ketobutyrate undergoes 
oxidative decarboxylation to propionyl-CoA, which through carboxylation yields D-methyl-malonyl-
CoA and subsequently L-methyl-malonyl-CoA, which is rearranged to succinyl-CoA.  
Homocysteine may be recycled back to methionine, which requires a folate derivative. Thus, folate 
deficiency may lead to a build-up of homocysteine.  
Transamination pathway:  
L-Methionine may be transaminated to alpha-keto-gamma-methylthiolbutyrate and then 
decarboxylated to 3-methylthioproprionyl CoA. From this the methylthiol moiety is cleaved to form 
methanethiol, which is subsequently metabolised to CO2 and sulphate.  
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III.4. Summary and Conclusions 
Studies have not been provided for the ADME of the candidate substance L-methionylglycine [FL-no: 
17.037], a dipeptide.  
If hydrolysed, the candidate substance will generate the two amino acids L-methionine and glycine, 
components of dietary protein. L-Methionine and glycine are metabolised to innocuous products at 
amounts that occur naturally in the diet. However, high intakes of single amino acids, may lead to 
amino acid imbalances and antagonism that may affect uptake, metabolism pathways and mechanisms 
of transport etc. The toxicity of L-methionine is mediated via the metabolite homocysteine. 
Peptides administered orally may be absorbed intact and have bioactivity, in general the longer the 
amino acid chain is the more bioactivity is lost during absorption, or conversely the shorter the amino 
acid chain the greater the possibility that bioactivity is retained. Without information about the 
potential for hydrolysis of the candidate substance, and without any studies that show the fate of the 
substance in vitro or in vivo, it is not possible to predict whether it will be absorbed as a dipeptide or 
not, nor its distribution or immediate fate after absorption, e.g. if there is any tissue specific 
availability or specificity for utilization of this dipeptide. Since such information is lacking, rapid 
metabolism of the dipeptide to innocuous metabolites cannot be anticipated. 
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ABBREVIATIONS 
ACE  Angiotensin I converting enzyme 
ADI  Acceptable Daily Intake 
ADME  Absorption, Distribution, Metabolism, and Excretion 
ANS  Additives and Nutrient Sources 
ATP  Adenosintriphosfat 
CAS  Chemical Abstract Service 
CEF Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
Chemical Abstract Service 
CHO  Chinese hamster ovary (cells) 
CoA  Coenzyme A 
CoE  Council of Europe 
DNA  Deoxyribonucleic acid 
EC  European Commission 
EFFA  European Flavour and Fragrance Association 
EFSA  The European Food Safety Authority 
EU  European Union 
FAO  Food and Agriculture Organization of the United Nations 
FDA  Food and Drug Administration 
FEMA  Flavor and Extract Manufacturers Association 
FGE  Flavouring Group Evaluation  
FLAVIS (FL) Flavour Information System (database) 
ID   Identity 
IOFI  International Organization of the Flavour Industry 
IR   Infrared spectroscopy 
JECFA  The Joint FAO/WHO Expert Committee on Food Additives 
LD50  Lethal Dose, 50 %; Median lethal dose 
MS  Mass spectrometry 
MSDI  Maximised Survey-derived Daily Intake 
mTAMDI Modified Theoretical Added Maximum Daily Intake 
NAD  Nicotinamide Adenine Dinucleotide  
NADH  Reduced Nicotinamide Adenine Dinucleotide 
NADP  Nicotinamide Adenine Dinucleotide Phosphate 
No  Number 
NOAEL No Observed Adverse Effect Level 
NOEL  No Observed Effect Level 
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NTP  National Toxicology Program 
PepT1  Peptide Transporter 1 
Pi   Inorganic Phosphate 
PPi  Inorganic Pyrophosphate 
SCE  Sister Chromatid Exchange 
SCF  Scientific Committee on Food 
SMART  Somatic Mutation and Recombination Test  
TAMDI Theoretical Added Maximum Daily Intake 
UDS  Unscheduled DNA Synthesis  
WHO  World Health Organisation 
